An update on the first clinical trial evaluating a pluripotent stem cell-derived neural stem cell therapy for Huntington's ...

IXICO plc (LSE:IXI) has maintained its upgraded revenue guidance for 2026 and 2027 despite the cancellation of two Huntington ...

An update on the first clinical trial evaluating a pluripotent stem cell‑derived neural stem cell therapy for Huntington’s ...

Western researcher Patrick O’Donoghue advances Huntington’s disease research with tRNA-based strategies to suppress toxic proteins and improve treatments.

A new imaging study found that tau-related changes in specific brain regions emerge before Huntington’s disease becomes ...

An update on the first clinical trial evaluating a pluripotent stem cell-derived neural stem cell therapy for Huntington's disease was presented today at the ISSCR 2026 Annual Meeting.

The demise of the two programmes still leaves Roche with one Huntington's candidate, the gene therapy RG6662, which is in a ...

The hereditary disorder Huntington's disease has so far been considered incurable. Its clinical manifestations include ...

Roche has halted development on two of its Huntington’s disease prospects, delivering another blow to a patient community that has long awaited new medicines. The Swiss drugmaker explained its ...

A drug has blocked the brain process that kills cells in incurable Huntington's disease—and works in human cells.

A study found that stimulating a specific inhibitory brain cell restored normal brain activity and improved movement in ...

The Swiss pharmaceutical giant told patient groups tominersen didn't delay disease progression in one trial, while a study of ...